News

Benlysta Plus Standard of Care Improved Disease Activity in Phase 3 Northeast Asia Trial

Benlysta (belimumab) used in combination with standard of care significantly improved disease activity and reduced prednisone use in patients in Northeast Asia with systemic lupus erythematosus (SLE), a Phase 3 clinical trial found. While the therapy is already approved in the U.S. and Europe for patients with active, autoantibody-positive SLE receiving standard…

SLE Patients with Pulmonary Arterial Hypertension Have ‘Relatively Good’ Survival Rates, Study Shows

A retrospective study shows that 83.9 percent of patients suffering from systemic lupus erythematosus (SLE) and pulmonary arterial hypertension survive at least five years after diagnosis. Also, those with anti-U1-RNP antibodies tend to have better survival rates, the study shows. The research, “Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus:…

Corbus Initiates Phase 2 Trial Evaluating Anabasum to Treat Lupus Patients

Corbus Pharmaceuticals recently started a Phase 2 clinical trial evaluating anabasum as an investigational therapy for the treatment of systemic lupus erythematosus (SLE). Anabasum is a synthetic endocannabinoid mimetic drug, meaning it mimics the action of endocannabinoids, which are endogenous molecules that bind to cannabinoid receptors in the nervous system. The drug…

Lupus Patients More Likely to Develop Atherosclerosis, Study Suggests

Patients with systemic lupus erythematosus (SLE) have higher incidence of subclinical atherosclerosis markers compared to heathy people, a French study shows. Understanding how cardiovascular disease develops in lupus patients may help establish better, personalized therapeutic strategies, including in patients who have no history of cardiovascular disease. The study, “…